Skip to content Skip to footer
Subscribe Now
NEWS

Dualitas Therapeutics and Roche Partner to Advance Novel Bispecific Antibodies for I&I Diseases in a ~$1B Deal

Shots: Dualitas has entered into a research collaboration & license agreement with Roche to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases, using Dualitas' DualScreen Bispecific Discovery Engine As per the deal, Dualitas will receive $36.5M upfront & additional research, development & commercial milestone payments, representing the total deal value of ~$1B, in addition…
3 days ago

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States  Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity   Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress
EVENTS

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress

Event description: Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-US Edition to be held on 28th June - 1st July 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers, and scientists from research institute pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC's,…
June 15, 2021

Read more